Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy (DMD)
Biotech
Wave surfs DMD success to regulators' doors, sending stock up
Wave has met its goal in a Duchenne muscular dystrophy study, positioning it to talk to regulators about accelerated approval.
Nick Paul Taylor
Sep 24, 2024 9:51am
Capricor sells Europe rights to late-stage DMD therapy for $35M
Sep 18, 2024 5:55am
Dyne shakes up C-suite after hazy DMD data drop
Sep 3, 2024 11:49am
Analysts dig into Avidity's DMD win, revealing nuances in data
Aug 12, 2024 9:24am
Pfizer takes $230M hit after axing failed DMD gene therapy
Jul 30, 2024 8:15am
Pfizer faces phase 3 DMD fail after patient death
Jun 12, 2024 5:01pm
